Summit Therapeutics SMMT
NASDAQ SMMT
$16.40 +0.92 (+5.94%)
As of: Sep 29, 2026 · 3:59 PM EDT

Summit Therapeutics (SMMT) Notes Payables (2021 - 2024)

Updated

Summit Therapeutics' Notes Payables was $24.5 million in Q3 2024, down 75.5% from $100 million a year earlier and down 75.5% from the prior quarter.

Analysis

Summit Therapeutics (SMMT) Notes Payables (2021 - 2024) Analysis & Trends

At the end of FY2022, Notes Payables at Summit Therapeutics came in at $19.77 million.

  • The Q3 2024 figure marks the lowest quarterly Notes Payables since Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Summit Therapeutics 12.28 Bn 10.04 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 24.50 Mn
Jun 30, 2024 100.00 Mn
Sep 30, 2023 100.00 Mn
Dec 31, 2022 19.77 Mn
Mar 31, 2021 54.96 Mn
API Access

Summit Therapeutics Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=SMMT&period=max&api_key=YOUR_API_KEY